Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Size: px
Start display at page:

Download "Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation"

Transcription

1 Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

2 Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe advantages and disadvantages to DOAC use Compare efficacy and safety of DOACs with warfarin Describe adverse effect profile of DOACs Determine which patients are good candidates for DOAC therapy vs warfarin

3

4 Warfarin

5 Kinetics Absorption: complete Distribution: 99% protein binding Only FREE warfarin is available for use at VKORC1 Metabolism: broken down by cytochrome P450 enzymes in the liver R-warfarin primary via 3A4 S-warfarin (SERIOUS WARFARIN) primary via 2C9 2C9 inhibitors will RAISE INR significantly. 3A4 inhibitors will RAISE INR to a lesser extent. Elimination: 92% renal LOTS of reasons why genetics can have effects on warfarin

6 Factors that affect warfarin dosing Body size Age Renal function Liver function Drug-drug interactions Dietary vitamin K intake Acute & chronic illness Smoking Alcohol Physical activity Genetics Warfarin manufacturer

7

8 Warfarin PROS Effective Inexpensive INR monitoring Reversible CONS Variable Dosing INR Monitoring Drug-drug interactions Lifestyle interactions Requirement for anticoagulation care provider

9 Other Oral Options?

10 TSOACs / DOACs / NOACs Current favorite acronym: DOAC (Direct Oral AntiCoagulant) Mechanisms of action DIRECT binding to active sites of factor II (thrombin) or Xa DabigaTran (Pradaxa) T for THROMBIN rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa) factor Xa Cost per 30 days = $ Reversible?

11 The Clotting Cascade

12 What can we use DOACs for? The Big Three: (non-valvular) Atrial Fibrillation Treatment of Venous Thromboembolism (VTE) Prevention of Recurrent VTE Post-joint-replacement VTE Prophylaxis Still Being Investigated: VTE Associated with Cancer VTE Associated with Hypercoagulable State Patients with Bioprosthetic Heart Valves With Dual Antiplatelet Therapy (DAPT) Not For Use In: Mechanical Heart Valves Left Ventricular Assist Devices

13 Dabigatran (Pradaxa) Absorption: 3-7% bioavailable Dosage form relies on low gastric ph No opening/crushing capsules

14 Dabigatran (Pradaxa) Absorption: 3-7% bioavailable Dosage form relies on low gastric ph No opening/crushing capsules Distribution: 35% protein bound Metabolism: metabolized readily after absorption from dabigatran etexilate to the active moiety, dabigatran Gut: p-glycoprotein Elimination: 80% renal t 1/2 = hours in healthy people

15 Dabigatran (Pradaxa ) Dosage Forms Capsules: 150 mg, 110 mg, 75 mg Do not break, chew, or open capsules before administration. Keep in original bottle. Monitoring Serum creatinine Adverse Effects Risk of bleeding Dyspepsia (11.3%)

16 Dabigatran in Atrial Fibrilation: RE-LY P < superiority

17 Dabigatran in Atrial Fibrilation: RE-LY P = 0.31 Note: Dabigatran 150 mg increased the rate of GI bleeding (p<0.001), decreased ICH (p<0.001) when compared to warfarin.

18 Dabigatran in VTE: RE-COVER Rate of Recurrent VTE 5 P < for noninferiority warfarin (INR 2-3) 2.4 dabigatran 150mg BID

19 Dabigatran in VTE: RE-COVER Rate of Major Bleeding warfarin (INR 2-3) 1.6 dabigatran 150mg BID

20 Other Clinical Trials for Pradaxa RE-ALIGN: Mechanical Heart Valves RE-SONATE: prevention of recurrent VTE vs placebo RE-MEDY: prevention of recurrent VTE vs warfarin RE-NOVATE: prevention of VTE after hip replacement surgery (vs enoxaparin)

21 Dabigatran Dosing VTE prevention after hip-replacement surgery Crcl 30ml/min or above Crcl less than 30ml/min Crcl 50ml/min or above with P-gp inhibitor Crcl less than 50ml/min with P-gp inhibitor 220mg daily Avoid 220mg daily Avoid

22 Xa Inhibitors

23 Rivaroxaban (Xarelto) Absorption: % bioavailable Better absorption with smaller doses & with food Distribution: 92-95% protein binding Metabolism: Gut: p-glycoprotein Liver: CYP450 3A4 Elimination: 66% renal T 1/2 : 5-12 hours

24 Rivaroxaban (Xarelto ) Dosage Forms Tablets: 20 mg, 15 mg, 10 mg Breakable/Crushable Monitoring Renal function Adverse Effects Bleeding risk

25 Rivaroxaban in Atrial Fib: ROCKET-AF Rate of stroke or systemic embolism (%) P<0.001 for non-inferiority Warfarin Rivaroxaban

26 Rivaroxaban in Atrial Fib: ROCKET-AF Rate of major bleeding (%) Warfarin Rivaroxaban

27 Rivaroxaban in VTE: EINSTEIN Rate of Recurrent VTE P<0.001 for noninferiority 3 P=0.003 for noninferiority Rivaroxaban Warfarin Einstein DVT Einstein PE

28 Rivaroxaban in VTE: EINSTEIN 2.5 Rate of Major Bleeding (%) P=0.21 P= Rivaroxaban Warfarin Einstein DVT Einstein PE

29 Other Rivaroxaban Clinical Trials Einstein Choice: Rivaroxaban 10mg daily for extended prophylaxis of VTE RECORD 1-4: post-joint-replacement VTE prophylaxis PIONEER: low-dose riva + P2Y12 vs. ultra-low-dose riva + DAPT vs. VKA + DAPT for post-pci afib patients

30 Rivaroxaban Dosing

31 Apixaban (Eliquis) Absorption: 50% bioavailable No effect of food Distribution: 92-95% protein binding Metabolism: Gut: p-glycoprotein Liver: CYP450 3A4 Elimination: 27% renal T 1/2 : 7-15 hours

32 Apixaban (Eliquis ) Dosage Forms Tablets: 5 mg, 2.5 mg Breakable, crushable May be administered without regard to food Monitoring Serum creatinine Adverse Effects Risk of bleeding

33 Apixaban in Atrial Fibrillation: ARISTOTLE Rate of Stroke or Systemic Embolism (%) P=0.01 for superiority Warfarin Apixaban

34 Apixaban in Atrial Fibrillation: ARISTOTLE Rate of Major Bleed (%) 3 P< Warfarin Apixaban

35 Apixaban in VTE: AMPLIFY & AMPLIFY-EXT Rate of Recurrent VTE (%) in AMPLIFY Warfarin P<0.001 for non-inferiority 2.3 Apixaban Rate of Recurrent VTE (%) in AMPLIFY-EXT Apixaban 2.5mg BID P<0.001 for superiority of both doses vs placebo Apixaban 5mg BID 8.8 Placebo

36 Apixaban in VTE: AMPLIFY & AMPLIFY-EXT Rate of Major Bleeding (%) in AMPLIFY P< Warfarin Apixaban Rate of Major Bleeding (%) in AMPLIFY-EXT Apixaban 2.5mg BID Apixaban 5mg BID Placebo

37 Apixaban: Other Clinical Trials AVERROES: atrial fib trial vs. ASA ADVANCE 1-3: post-joint-replacement VTE prophylaxis

38 Apixaban Dosing Extended VTE treatment Without concomitant P- gp/cyp3a4 inhibitor With concomitant P- gp/cyp3a4 inhibitor 2.5mg BID Avoid

39 Edoxaban (Savaysa) Absorption: 62% bioavailable No effect of food Distribution: 55% protein binding Metabolism: Gut: p-glycoprotein Elimination: 50% renal T 1/2 : hours

40 Edoxaban (Savaysa ) Dosage Forms Tablets: 15mg, 30mg, 60mg May be administered without regard to food Monitoring Renal function Adverse Effects Risk of bleeding

41 Edoxaban Clinical Trials ENGAGE AF TIMI 48 (atrial fibrillation) Efficacy: non-inferior to warfarin Safety: less bleeding than warfarin HOKUSAI (VTE treatment) Efficacy: non-inferior to warfarin Safety: less bleeding than warfarin

42 Edoxaban Dosing Indication Dose Crcl 15-50ml/min Atrial fibrillation DVT/PE Crcl >95 ml/min Body weight < 60kg 60mg daily 30mg daily Do not use No adjustment 60mg daily (after 5-10 days of parenteral) 30mg daily No adjustment 30mg daily P-gp inhibitor No adjustment 30mg daily Post-joint replacement 30mg daily

43 DOAC Trial Data Summary Atrial Fibrillation DVT/PE treatment stroke prevention (compared to warfarin) rates of bleeding (compared to warfarin) rate of recurrent VTE (compared to LMWH bridged warfarin) rates of bleeding (compared to warfarin) Pradaxa (dabigatran) superior same same same Xarelto (rivaroxaban) same same same same Eliquis (apixaban) superior superior same superior Savaysa (edoxaban) same superior same superior

44 DOAC Drug-Drug Interactions Dabigatran (substrate of p-glycoprotein) Inducers (rifampin): avoid co-administration Inhibitors (dronedarone, ketoconazole): dose reduce or avoid (see prescribing info) Verapamil: separate by 2 hours Xa Inhibitors (substrates of CYP 3A4 & p-gp) Dual inducers (carbamazepine, phenytoin, phenobarb, rifampin, St. John s wort): avoid coadministration Dual inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin): reduce dose or avoid (see prescribing info)

45 Reversal Agents Supportive therapies (all anticoagulants) Fresh frozen plasma, fluids, blood products Prothrombin complex concentrates (all anticoagulants) 3-Factor: factors II, IX, X 4-Factor: factors II, VII, IX, X Warfarin: Vitamin K Dabigatran: idarucizumab (Praxbind) Xa Inhibitors: andexanet alfa (not available yet)

46 Peri-Procedural Management PLEASE DON T BRIDGE DOACs!!

47 The Ideal DOAC Patient Diagnosed with one of the Big Three Good kidney function Compliant with medications Average body size Not on strong p-gp or 3A4 inhibitors or inducers History of unstable INRs not related to medication noncompliance Commercially insured

48 Patient-Centered Care Indication & clinical data Patient preferences Don t make assumptions Utilize manufacturer assistance when appropriate Beware the donut hole

49 Clinical References at Your Fingertips Anticoagulationtoolkit.org European Heart Rhythm Associate Practical Guide on the Use of Non-Vitamin K Antagonist Anticoagulants in Patients with Non- Valvular Atrial Fibrillation

50 References Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January Connolly SJ et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. NEJM. 2009; 361: Schulman S et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. NEJM 2009; 361: Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; November Patel MR. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. NEJM 2011; 365: The Einstein Investigators. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. NEJM 2010; 363: Eliquis [Package insert]. Princeton, NJ: Bristol-Myers Squibb Company. July, Granger CB et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. NEJM 2011; 365: Agnelli G et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. NEJM 2013; 369: Agnelli G et al. Apixaban for Extended Treatment of Venous Thromboembolism. NEJM 2013: 368; Savaysa [package insert]. Parsippany, NJ. Daiichi Sankyo, Inc Giugliano RP et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. NEJM 2013; 369: The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. NEJM 2013; 369: ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. JACC 2017 epub ahead of print. Heidbuchel H et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15(5):

New Anticoagulants Therapies

New Anticoagulants Therapies New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

Drug Use Criteria: Direct Oral Anticoagulants

Drug Use Criteria: Direct Oral Anticoagulants Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

Direct Oral Anticoagulants

Direct Oral Anticoagulants Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),

More information

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation

Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist

More information

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives

The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease

Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy

More information

What s new with DOACs? Defining place in therapy for edoxaban &

What s new with DOACs? Defining place in therapy for edoxaban & What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas

More information

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review

More information

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS

NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions

More information

Anticoagulation: Novel Agents

Anticoagulation: Novel Agents Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),

More information

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular

More information

DIRECT ORAL ANTICOAGULANTS

DIRECT ORAL ANTICOAGULANTS 2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral

More information

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging

Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Comparison of novel oral anticoagulants (NOACs)

Comparison of novel oral anticoagulants (NOACs) Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic

More information

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator

Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications

More information

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio

Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015

Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology

More information

Southern Trust Anticoagulant Team

Southern Trust Anticoagulant Team CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute

More information

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine

Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole

More information

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching

to a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services } Identify the FDA approved direct oral anticoagulants (DOACs) } Distinguish the differences in the dosing of DOACs for various indications

More information

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants

New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives

More information

Novel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015

Novel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

Direct Oral Anticoagulants An Update

Direct Oral Anticoagulants An Update Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what

More information

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA

Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:

More information

An Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London

An Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations

More information

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016 Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic

More information

Master Class: DOAC Drug Interactions April 20, 2017

Master Class: DOAC Drug Interactions April 20, 2017 Master Class: DOAC Drug Interactions April 20, 2017 Sara R. Vazquez, PharmD, BCPS, CACP Clinical Pharmacist University of Utah Health Thrombosis Service Disclosures Financial Disclosures: none Off-label/investigational

More information

04/13/2015. Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement. Abbreviations. Learning Objectives TSOACS

04/13/2015. Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement. Abbreviations. Learning Objectives TSOACS 1 2 Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement I have nothing to disclose concerning possible financial or personal relationships with commercial entities

More information

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published

More information

TSHP 2014 Annual Seminar 1

TSHP 2014 Annual Seminar 1 Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical

More information

Technician Objectives. Pharmacist Objectives. Replacing Warfarin. Gaps in Practice. Target-Specific Anticoagulants: Clinical Update and

Technician Objectives. Pharmacist Objectives. Replacing Warfarin. Gaps in Practice. Target-Specific Anticoagulants: Clinical Update and Target-Specific Anticoagulants: Clinical Update and Considerations Erika Hellenbart, PharmD, BCPS September 13,2014 Target-Specific Anticoagulants: Clinical Update and Considerations Erika Hellenbart,

More information

Dr Calum Young Cardiologist Tauranga

Dr Calum Young Cardiologist Tauranga Dr Calum Young Cardiologist Tauranga 8:30-9:25 WS #93: New Oral Anticoagulant Drugs and Management of AF 9:35-10:30 WS #105: New Oral Anticoagulant Drugs and Management of AF (Repeated) GPCME 2016: Anticoagulation

More information

NOAC s across indications

NOAC s across indications Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich

More information

Xarelto (rivaroxaban)

Xarelto (rivaroxaban) Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto

More information

The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for

The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,

More information

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin 1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,

More information

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,

More information

David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy

David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Anticoagulation Task Force

Anticoagulation Task Force Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration

More information

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial

More information

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD

When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven

More information

Anticoagulation Therapy in LTC

Anticoagulation Therapy in LTC Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation

More information

New Antithrombotic Agents DISCLOSURE

New Antithrombotic Agents DISCLOSURE New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What

More information

Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto

Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident

More information

The Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015

The Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi

More information

Treatment Options and How They Work

Treatment Options and How They Work Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the

More information

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS

More information

Professional Practice Minutes December 7, 2016

Professional Practice Minutes December 7, 2016 Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon

More information

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto

Atrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto

More information

Old and New Anticoagulants For Stroke Prevention Benefits and Risks

Old and New Anticoagulants For Stroke Prevention Benefits and Risks Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry

More information

Anticoagulation in 2014: Using the New Agents Safely

Anticoagulation in 2014: Using the New Agents Safely Anticoagulation in 2014: Using the New Agents Safely Tracy Minichiello, M.D. Professor of Medicine University of California, San Francisco Chief, SF VA Anticoagulation & Thrombosis Service Disclosures

More information

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE

Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an

More information

The clinical relevance of AMPLIFY programme

The clinical relevance of AMPLIFY programme Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer

More information

Pradaxa (dabigatran)

Pradaxa (dabigatran) Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa

More information

New Antithrombotic Agents

New Antithrombotic Agents New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)

They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health

More information

USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY

USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12

More information

Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist

Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Peter Thomson, Pharm D. Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Clinical

More information

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from

More information

A Cascade of Updates: Hot Topics in Anticoagulation

A Cascade of Updates: Hot Topics in Anticoagulation A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate

More information

Getting the Most from DOAC Therapy:

Getting the Most from DOAC Therapy: Getting the Most from DOAC Therapy: Minimizing Risk and Maximizing Adherence Brent N. Reed, Pharm.D., BCPS AQ Cardiology University of Maryland School of Pharmacy Stuart T. Haines, Pharm.D., BCPS, BCACP,

More information

ADVANCES IN ANTICOAGULATION

ADVANCES IN ANTICOAGULATION ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants

More information

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Anticoagulatns New Agents, Reversal and Bridging William

More information

New Oral Anticoagulant Drugs in the Prevention of DVT

New Oral Anticoagulant Drugs in the Prevention of DVT New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X

More information

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis

More information

Acute Care: Understanding Direct Oral Anticoagulants (DOACs)

Acute Care: Understanding Direct Oral Anticoagulants (DOACs) Acute Care: Understanding Direct Oral Anticoagulants (DOACs) National Conference for Nurse Practitioners (NCNP) October 11, 2017 John Togami, PharmD, PhC Pharmacist Clinician - Outpatient Anticoagulation

More information

The (Hopefully) Bloodless Battle for Safe Use of DOACs. Gale E. Garmong, PharmD Clinical/Staff Pharmacist Klingensmith s Drug Stores

The (Hopefully) Bloodless Battle for Safe Use of DOACs. Gale E. Garmong, PharmD Clinical/Staff Pharmacist Klingensmith s Drug Stores The (Hopefully) Bloodless Battle for Safe Use of DOACs Gale E. Garmong, PharmD Clinical/Staff Pharmacist Klingensmith s Drug Stores Objectives At the completion of this activity, the participant will be

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million

More information

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia 6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac

More information

Updates in Management of Venous Thromboembolic Disease

Updates in Management of Venous Thromboembolic Disease Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures

More information

ESC Congress 2012, Munich

ESC Congress 2012, Munich ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,

More information

Disclosure and Conflict of Interest

Disclosure and Conflict of Interest A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate

More information

Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention

Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania

More information

The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.

The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban

More information

Scoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview

Scoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September

More information

Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY

Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY Jedi Training 101: Mind-tricks & Evidence -Based Approaches to Combating Clinical Controversies in Anticoagulation Therapy Kelly Rudd, PharmD, FCCP, BCPS, CACP Basset Medical Center, Cooperstown, NY LEARNING

More information

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Appendix C Factors to consider when choosing between anticoagulant options and FAQs Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened

More information

When and how to combine antiplatelet agents and anticoagulant?

When and how to combine antiplatelet agents and anticoagulant? When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation

More information